Like the wider regional banking industry, Nashville-based Pinnacle Financial Partners has been a good performer since my opening piece, returning around 20%. Pinnacle recently released second quarter results. While loan growth and credit quality may have been areas for concern a few months ago, both remain solid. Pinnacle's shares have re-rated back toward the 2x tangible book value area, leaving them less attractive than they were a few months ago.

Fastenal delivered strong Q2 results, driven by big-ticket customer growth, market share gains, and expanding digital sales footprint. Operating leverage from its digital solutions is boosting margins and keeping SG&A growth in check. Risks include a slowdown in new FMI device signings and elevated inventory.

NKE's global reach faces near-term strain from weak demand and cost pressures, but long-term strategy fuels recovery hopes.

EFX is set to report Q2 results on July 22, with EPS and revenues expected to rise on solid USIS, international and Workforce Solutions gains.

NEW YORK , July 17, 2025 /PRNewswire/ -- Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces the release of Club Offers for Club Members in the U.S. Rigorously vetted and negotiated for us travel enthusiasts: $299—NAPA RETREAT WITH UPGRADE AND $164 IN PERKSWith this Napa getaway, Club Members save 50% on an upgraded room with vineyard views. Perks include breakfast, self-parking, a waived resort fee and $40 daily credit.

I prefer BBJP over EWJ for its lower expense ratio and similar sector exposures, making it a more efficient Japan ETF choice. Tariff risks threaten Japan's export-heavy sectors, especially autos and industrials, despite some natural hedging benefits from an also weakening Yen. These natural hedging benefits are affected by the significant US exposure in geographic mixes, but also the likelihood of harsher competition in remaining markets under reconfigured trade flows.

Key Points in This Article: SoFi Technologies‘ (SOFI) 150% stock surge since April is driven by strong revenue growth, student loan demand, and crypto expansion plans.

ROP's Q2 2025 earnings are likely to rise 7.6% on strong SaaS momentum, but margin pressure from rising costs looms.

The company says it also will make crypto trading available in other markets later this year, though it didn't specify where.

Since early May, insider buying activity has surged at three major companies. Together, top executives and influential insiders have invested more than $170 million of their own money, sending a strong signal of confidence in the future of these stocks.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped on a sweeping restructuring plan that includes cutting about 500 jobs, or 36% of its workforce, in a move aimed at reducing annual operating expenses by $400 million by 2026. The biotech company said it will sharpen its focus on high-impact drug development programs, particularly its small interfering RNA (siRNA) platform targeting neurodegenerative and pulmonary diseases such as facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy type 1, and Huntington's disease.

Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.

Key Points These dividend stocks yield 5% or more.

GE beat Q2 estimates with 38% EPS growth and 23% adjusted revenue gain, driven by strength in commercial engines and services.

PepsiCo, Inc. (NASDAQ:PEP ) Q2 2025 Earnings Conference Call July 17, 2025 8:15 AM ET Company Participants James T. Caulfield - Executive VP & CFO Ramon Luis Laguarta - Chairman & CEO Ravi Pamnani - Senior Vice President of Investor Relations Conference Call Participants Andrea Faria Teixeira - JPMorgan Chase & Co, Research Division Bonnie Lee Herzog - Goldman Sachs Group, Inc., Research Division Christopher Michael Carey - Wells Fargo Securities, LLC, Research Division Dara Warren Mohsenian - Morgan Stanley, Research Division Filippo Falorni - Citigroup Inc., Research Division Kaumil S.

Novartis AG delivered strong Q2 2025 results, outpacing expectations, but faces looming patent expiries for major drugs like Entresto, Tasigna, and Promacta. Growth in new and existing pipeline drugs, plus robust financials and buybacks, position Novartis for resilience despite upcoming revenue headwinds. While the company's long-term outlook remains positive, current valuation already reflects its strengths, making shares fairly valued at this time.

Amphenol hovers near its 52-week peak as end-market expansion and targeted acquisitions drive growth momentum.

POWL's planned Remsdaq acquisition aims to boost automation offerings and expand its footprint in the utility market.

The Census Bureau's Advance Retail Sales Report for June showed consumer spending was higher than expected last month, with headline sales rising 0.6%. This marks the first monthly increase since March and was better than the expected 0.1% rise.

SHENZHEN, China , July 17, 2025 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, announced that they have purchased up to $200 million in Bitcoin and cryptocurrency-related securities derivatives. As of July 17 , the cumulative investment income has reached $34.67million.